Posted by Michael Wonder on 20 Jul 2016
Valeant and Progenics announce FDA approves Relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain
19 July 2016 - Valeant Pharmaceuticals and Progenics Pharmaceuticals, Inc. today announced that the U.S. FDA has approved Relistor (methylnaltrexone bromide) tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
Valeant expects to commence sales of Relistor tablets in the U.S. in the third quarter of 2016.
Previously, Relistor subcutaneous Injection (12 mg and 8 mg) was approved in 2008 for the treatment of opioid-induced constipation (OIC) in adults with advanced illness who are receiving palliative care and in 2014 for the treatment of OIC in adults with chronic non-cancer pain.
